The 5‐HT3 Antagonist MDL‐72222 Exacerbates Ethanol Withdrawal Seizures in Mice

Kathleen A. Grant, Kaisa Hellevuo, Boris Tabakoff

    Research output: Contribution to journalArticlepeer-review

    25 Scopus citations

    Abstract

    Ethanol‐dependent mice were treated with the 5‐HT3 antagonist MDL 72222 after withdrawal from ethanol. Treatment with unit doses (0, 5.6, 10, and 17.0 mg/kg) of MDL 72222 at 0, 4, and 7 hr after withdrawal dose‐dependently exacerbated the severity of ethanol withdrawal seizures. Treatment with a single dose (17 mg/kg) of MDL 72222 at 5 hr after withdrawal also exacerbated the severity of ethanol withdrawal seizures. Ethanol naive mice treated with MDL 72222 (56 mg/kg) did not display any seizures. Treatment with another 5‐HT3 antagonist, ICS 205‐930 (23 and 46 mg/kg), or the 5‐ HT2 receptor antagonist ketanserin, did not affect ethanol withdrawal seizures. The findings suggest MDL 72222 selectively enhances sensitivity to withdrawal seizures following chronic ethanol exposure.

    Original languageEnglish (US)
    Pages (from-to)410-414
    Number of pages5
    JournalAlcoholism: Clinical and Experimental Research
    Volume18
    Issue number2
    DOIs
    StatePublished - Apr 1994

    Keywords

    • 5‐HT Antagonists
    • Alcohol Dependence
    • Drug Withdrawal Seizures
    • Serotonin

    ASJC Scopus subject areas

    • Medicine (miscellaneous)
    • Toxicology
    • Psychiatry and Mental health

    Fingerprint Dive into the research topics of 'The 5‐HT<sub>3</sub> Antagonist MDL‐72222 Exacerbates Ethanol Withdrawal Seizures in Mice'. Together they form a unique fingerprint.

    Cite this